Epigenetic inhibitors with PARPis: A novel therapeutic strategy for BRCA-proficient pancreatic cancer
18 Aug 2025
Patient-derived pancreatic cancer organoids showed significant growth inhibition when treated with decitabine, an epigenetic inhibitor. Noticeably, the combination of decitabine with a PARP inhibitor showed pronounced synergism in inhibiting tumour organoid growth.
By employing the 6-base genome via duet evoC, researchers at the University of Maryland have identified differentially methylated genes that may be responsible for therapy resistance and tumor aggression in pancreatic cancer.
About the company
biomodal
biomodal is an omics-based life sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic information from a single, low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution, phased sequencing approach unlocks the combinatorial power of genetic and epigenetic information in one workflow, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.
Related products
Request Quote for All Products
duet multiomics solution evoC
biomodalYour single solution for multiomics data - Uncover a true 6-base genome for unprecedented insights into current and future biological states. Access all four canonical bases and distinguish 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) from a single 5ng DNA sample, in a single experiment, with high accuracy.
